Spots Global Cancer Trial Database for nasopharyngeal carcinoma (npc)
Every month we try and update this database with for nasopharyngeal carcinoma (npc) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | NCT03769467 | Nasopharyngeal ... Nasopharyngeal ... Epstein-Barr Vi... Epstein-Barr Vi... Epstein-Barr Vi... | tabelecleucel pembrolizumab | 12 Years - | Atara Biotherapeutics | |
A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA | NCT02363400 | Nasopharyngeal ... | MEP | 20 Years - | National Health Research Institutes, Taiwan | |
Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma | NCT01536223 | Chemoradiation Nasopharyngeal ... | PF (cisplatin a... TPF (docetaxel ... | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma | NCT01536223 | Chemoradiation Nasopharyngeal ... | PF (cisplatin a... TPF (docetaxel ... | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT | NCT02735317 | Nasopharyngeal ... Stomatitis | Oral Ulcer Garg... Quadruple mixtu... | 18 Years - 65 Years | Sun Yat-sen University | |
A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients | NCT02578641 | Nasopharyngeal ... | autologous EBV ... combination IV ... | 18 Years - | Tessa Therapeutics | |
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors | NCT04215978 | Advanced Solid ... Non Small Cell ... Head and Neck S... Nasopharyngeal ... | BGB-A445 tislelizumab | 18 Years - | BeiGene | |
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | NCT03769467 | Nasopharyngeal ... Nasopharyngeal ... Epstein-Barr Vi... Epstein-Barr Vi... Epstein-Barr Vi... | tabelecleucel pembrolizumab | 12 Years - | Atara Biotherapeutics |